Could natural immune cells help fight leukemia drug resistance?
NCT ID NCT04965649
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study from France examined whether a specific type of immune cell (innate CD8+ T cells) is linked to how quickly resistance mutations develop in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Researchers analyzed blood samples from 30 adult patients already being treated with tyrosine kinase inhibitors (TKIs). The goal was to see if higher levels of these immune cells are associated with slower growth of drug-resistant cancer cells. This is an observational study, not a treatment trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could point toward new ways to predict or overcome drug resistance in certain leukemias.
- What could go wrong
- This is a small, completed observational study (30 participants) that only looks for associations, not a treatment. Results may not lead to direct patient benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BCR-ABL POSITIVE ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nîmes
Nîmes, Gard, 30029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor's DNA guide better cancer care for kids?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a smart tool keep watch on leukemia after treatment stops?
- Can donor immune cells tame stem cell transplant risks?
- A guided path back to work after blood cancer: a trial tests the impact
- Can a new tracer light up cancer growth?